Human HVEM, recombinant (C-Fc)

Human HVEM, recombinant (C-Fc)
Item number Size Datasheet Manual SDS Delivery time Quantity Price
NOV-C810.10ug 10 µg - -

10 - 15 business days*

70.00€
NOV-C810.50ug 50 µg - -

10 - 15 business days*

150.00€
NOV-C810.500ug 500 µg - -

10 - 15 business days*

665.00€
NOV-C810.1mg 1 mg - -

10 - 15 business days*

950.00€
 
Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 14 is produced by our... more
Product information "Human HVEM, recombinant (C-Fc)"
Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 14 is produced by our Mammalian expression system and the target gene encoding Leu39-Val202 is expressed with a human IgG1 Fc tag at the C-terminus. Protein function: Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network (PubMed:9462508, PubMed:10754304, PubMed:18193050, PubMed:23761635). Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation (PubMed:19915044, PubMed:9153189, PubMed:9162022). Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions (PubMed:10754304). Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response (PubMed:23761635). In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and proinflammatory cytokines. Upon binding to CD160 on activated CD4+ T cells, downregulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with BTLA (PubMed:19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed:19915044). [The UniProt Consortium]
Keywords: TR2, HVEA, HveA, CD270, Herpesvirus entry mediator A, Herpes virus entry mediator A, Tumor necrosis factor receptor-like 2, Tumor necrosis factor receptor superfamily member 14, Recombinant Human HVEM (C-Fc)
Supplier: Novoprotein
Supplier-Nr: C810

Properties

Conjugate: No
Host: Human cells
Species reactivity: human
MW: 44.5 kD
Format: Lyophilized

Database Information

KEGG ID : K05152 | Matching products
UniProt ID : Q92956 | Matching products

Handling & Safety

Storage: -20°C (+4 °C for short term storage)
Shipping: +20°C (International: +20°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Human HVEM, recombinant (C-Fc)"
Write a review
or to review a product.
Viewed